Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model

Saab S, Hunt DR, Stone MA, McClune A, Tong MJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1002/lt.22072

Indexing Status
Subject indexing assigned by NLM

MeSH
Antiviral Agents /administration & dosage /economics; Carcinoma, Hepatocellular /therapy /virology; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Genotype; Graft Rejection /prevention & control /virology; Graft Survival /drug effects; Hepacivirus /genetics; Hepatitis C /complications /diagnosis /drug therapy /economics /mortality /surgery; Humans; Interferons /administration & dosage /economics; Liver Cirrhosis /diagnosis /drug therapy /economics /mortality /surgery /virology; Liver Neoplasms /therapy /virology; Liver Transplantation /adverse effects /economics /mortality; Markov Chains; Middle Aged; Patient Selection; Quality-Adjusted Life Years; RNA, Viral /blood; Recurrence; Ribavirin /administration & dosage /economics; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load

AccessionNumber
22010001266

Date bibliographic record published
24/11/2010